Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

22.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term safety and preliminary patient-reported outcomes of bipolar radiofrequency therapy for mild-to-moderate erectile dysfunction: a prospective single-arm pilot study.

Translational andrology and urology·2026
Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026
Same author

Floppy glans syndrome revisited: a modern classification and mechanistic framework for distal penile support deficiency following penile prosthesis placement.

The journal of sexual medicine·2026
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.

NPJ precision oncology·2026
Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026

Related Experiment Video

Updated: Oct 28, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.6K

Improving outcomes in germ cell cancers using miRNA.

Ciara Conduit1, Ben Tran2

  • 1Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Therapeutic Advances in Medical Oncology
|July 15, 2021
PubMed
Summary

Testicular cancer is highly curable, but current biomarkers are insufficient. Micro-ribonucleic acids (miRNAs), specifically miR-371a-3p, show promise as sensitive and specific biomarkers for improved clinical management.

Keywords:
blood-based biomarkergerm cell tumourmolecular oncologypredictive biomarkerprognostic biomarker

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Related Experiment Videos

Last Updated: Oct 28, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.6K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Testicular cancer has seen significant treatment advances, leading to high curability over the past 50 years.
  • Existing serum tumor and imaging biomarkers for testicular cancer lack the necessary sensitivity, specificity, and predictive value.
  • Current biomarkers have limited utility in detecting active malignancy and guiding treatment decisions for many patients.

Purpose of the Study:

  • To review the technological evolution and clinical relevance of micro-ribonucleic acids (miRNAs) as potential biomarkers for testicular cancer.
  • To highlight the potential of miR-371a-3p in addressing the limitations of current diagnostic tools.
  • To discuss the future clinical application of miRNA-based diagnostics in testicular cancer management.

Main Methods:

  • Review of existing literature on testicular cancer biomarkers.
  • Analysis of the role and potential of micro-ribonucleic acids (miRNAs), particularly miR-371a-3p.
  • Discussion of technological advancements and limitations related to miRNA detection.

Main Results:

  • Micro-ribonucleic acids (miRNAs), exemplified by miR-371a-3p, demonstrate potential to overcome the sensitivity and specificity issues of current testicular cancer biomarkers.
  • Early data suggests miRNAs can effectively fill the diagnostic gaps left by conventional markers.
  • The technology for miRNA detection is evolving, with ongoing research into its clinical utility.

Conclusions:

  • miR-371a-3p and other miRNAs represent a promising new class of biomarkers for testicular cancer.
  • Further research and validation are needed to fully integrate miRNA diagnostics into clinical practice.
  • MiRNAs hold the potential to significantly improve the management and treatment decisions for patients with testicular cancer.